Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Clinical Insight

Qiagen has added new capabilities to the Qiagen Clinical Insight (QCI), its clinical decision support solution, which streamlines the annotation, interpretation and reporting of next-generation sequencing results for clinical laboratories.

Specifically, the company has expanded the solution to include support for leukemia and lymphoma testing as well as testing for hereditary cancers including breast and ovarian cancer, Lynch syndrome, Peutz-Jegher syndrome, ataxia telangiectasia, neurofibromatosis, hereditary diffuse gastric cancer, familial prostate cancer, polyposis, and many more. —This is in addition to existing support for analyzing somatic mutations in solid tumors. The updated software also offers new features for diagnostic testing as well as monitoring and progression, support for copy number variations and fusion genes, and additional prognostics data from the literature. It also provides comprehensive coverage of FDA- and EMA-approved drug labels, NCCN, ASCO and ESMO professional guidelines, and active genotype-related clinical trials.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more